1. Home
  2. CET vs NVAX Comparison

CET vs NVAX Comparison

Compare CET & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

N/A

Current Price

$54.40

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$10.12

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
NVAX
Founded
1929
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CET
NVAX
Price
$54.40
$10.12
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
28.8K
4.8M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
64.69
52 Week Low
$47.82
$6.20
52 Week High
$55.99
$11.85

Technical Indicators

Market Signals
Indicator
CET
NVAX
Relative Strength Index (RSI) N/A 76.33
Support Level N/A $8.42
Resistance Level N/A $10.90
Average True Range (ATR) 0.00 0.54
MACD 0.00 0.22
Stochastic Oscillator 0.00 97.41

Price Performance

Historical Comparison
CET
NVAX

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: